Design, Synthesis and Biological Evaluation of N4-Sulfonamido-Succinamic, Phthalamic, Acrylic and Benzoyl Acetic Acid Derivatives as Potential DPP IV Inhibitors



Reema Abu Khalaf1, *, Ghassan Abu Sheikha1, Mahmoud Al-Sha'er2, Mutasem Taha3
1 Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan;
2 Faculty of Pharmacy, Zarqa University, Zarqa, Jordan;
3 Drug Discovery Unit, Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan, Amman, Jordan


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 1560
Abstract HTML Views: 455
PDF Downloads: 180
Total Views/Downloads: 2195
Unique Statistics:

Full-Text HTML Views: 463
Abstract HTML Views: 253
PDF Downloads: 108
Total Views/Downloads: 824



© Abu Khalaf et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan; Tel: 00962 6 4291511 ext. 239; Fax: 00962 6 4291432; E-mails: reema.abukhalaf@zuj.edu.jo and rima_abu_khalaf@yahoo.com


Abstract

As incidence rate of type II diabetes mellitus continues to rise, there is a growing need to identify novel therapeutic agents with improved efficacy and reduced side effects. Dipeptidyl peptidase IV (DPP IV) is a multifunctional protein involved in many physiological processes. It deactivates the natural hypoglycemic incretin hormone effect. Inhibition of this enzyme increases endogenous incretin level, incretin activity and should restore glucose homeostasis in type II diabetic patients making it an attractive target for the development of new antidiabetic drugs. One of the interesting reported anti- DPP IV hits is Gemifloxacin which is used as a lead compound for the development of new DPP IV inhibitors. In the current work, design and synthesis of a series of N4-sulfonamido-succinamic, phthalamic, acrylic and benzoyl acetic acid derivatives was carried out. The synthesized compounds were evaluated for their in vitro anti-DPP IV activity. Some of them have shown reasonable bioactivity, where the most active one 17 was found to have an IC50 of 33.5 μM.

Keywords: Acrylic acid, docking, DPP IV inhibitors, pharmacophore modeling, phthalamic acid, succinamic acid, type II diabetes.